Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
This reimbursement policy governs when fecal laboratory analyses—either for diagnosing intestinal dysbiosis or for screening donors prior to fecal microbiota transplantation (FMT)—are eligible for reimbursement under Blue Cross Blue Shield of New Mexico plan documents and applicable provider contracts.
Document updated with literature review. Reimbursement Information unchanged.
Edited reimbursement lists to clarify that FMT testing applies to donor samples and clarified item 4.h.
Procedure code list changed over time (codes added and removed in prior updates).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.